Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD

Kidney International

Volumn 53, Issue 1, 1998, Pages 205-211

  Kuizon, Beatriz D ^b   Goodman, William G ^b   Jüppner, Harald ^b   Boechat, Ines ^b   Nelson, Pauline ^b   Gales, Barbara ^b   Salusky, Isidro B ^a  

^a UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Calcitriol therapy; Chondrocyte activity; End stage renal disease; Growth in children

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CARBON DIOXIDE; PARATHYROID HORMONE; PHOSPHORUS;

ARTICLE; BODY HEIGHT; BONE LESION; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PREPUBERTY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 0031888062     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00724.x     Document Type: Article

References (41)

1. 3 in childhood renal osteodystrophy. N Engl J Med 298:238-242, 1978
2. 3 on renal function, mineral balance, and growth in children with severe chronic renal failure. Pediatrics 68:559-571, 1981
3. SALUSKY IB, COBURN JW, BRILL J, FOLEY J, SLATOPOLSKY E, FINE RN, GOODMAN WG: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975-982, 1988
4. GOODMAN WG, SALUSKY IB: Evolution of secondary hyperparathyroidism during daily oral calcitriol therapy in pediatric renal osteodystrophy. Contrib Nephrol 90:189-195, 1991
5. MARTIN KJ, BULLAL HS, DOMOTO DT, BLALOCK S, WEINDEL M: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: Preliminary observations. Am J Kidney Dis 19:540-545, 1992
6. ANDRESS DL, NORRIS KC, COBURN JW, SLATOPOLSKY EA, SHERRARD DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
7. SLATOPOUSKY E, WEERTS C, THIELAN J, HORST RL, HARTER H, MARTIN KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
8. GOODMAN WG, RAMIREZ JA, BELIN TR, CHON Y, GALES B, SEGRE GV, SALUSKY IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166, 1994
9. CANO F, DELUCCHI A, WOLFF E, RODRIGUEZ E, FUENTES A: Calcitriol oral pulse therapy in children with renal osteodystrophy. Pediatr Nephrol 9:606-608, 1995
10. KLAUS G, MEHLS O, HINDERER J, RITZ E: Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet 337:800-801, 1991
11. DELMEZ JA, DOUGAN CS, GEARING BK, ROTHSTEIN M, WINDUS DW, RAPP N, SLATOPOLSKY E: The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 31:795-799, 1987
12. WARADY BA, HEBERT D, SULLIVAN EK, ALEXANDER SR, TEJANI A: Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 11:49-64, 1997
13. 3 effects in primary cultures of growth cartilage cells of the rat. Calcif Tissue Int 49:340-348, 1991
14. SALUSKY IB, COBURN JW, FOLEY J, NELSON P, FINE RN: Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 108:767-770, 1986
15. SALUSKY IB, FINE RN, NELSON P, BLUMENKRANTZ MJ, KOPPLE JD: Nutritional status of children undergoing continuous ambulatory peritoneal dialysis. Am J Clin Nutr 38:599-611, 1983
16. PARFITT AM, DREZNER MK, GLORIEUX FH, KANIS JA, MALLUCHE HH, MEUNIER PJ, OTT SM, RECKER RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610, 1987
17. HAMMILL PVV, DRIZD TA, JOHNSON CL, REED RB, ROCHE AF: NCHS GROWTH CURVES FOR CHILDREN BIRTH - 18 YEARS, HYATTS-VILLE, NATIONAL CENTER FOR HEALTH STATISTICS, DHEW PUBL No 78-1650, 1977
18. GREULICH WW, PYLE SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist. Palo Alto, Stanford University Press, 1959
19. SALUSKY IB, RAMIREZ JA, OPPENHEIM WL, GALES B, SEGRE GV, GOODMAN WG: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253-258, 1994
20. MEHLS O, RITZ E, GILLI G, WANGDAK T, KREMPIEN B: Effect of vitamin D on growth in experimental uremia. Am J Clin Nutr 31:1927-1931, 1978
21. HODSON EM, EVANS RA, DUNSTAN CR, HILLS E, WONG SY, ROSENBERG AR, ROY LP: Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol. Clin Nephrol 24:192-200, 1985
22. CHAN JCM, MCENERY PT, CHINCHILLI VM, ABITBOL CL, BOINEAU FG, FRIEDMAN AL, LUM GM, ROY S III, RULEY EJ, STRIFE CF: A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. J Pediatr 124:520-528, 1994
23. SALUSKY IB, FINE RN, KANGARLOO H, GOLD R, PAUNIER L, GOODMAN WG, BRILL JE, GILLI G, SLATOPOLSKY E, COBURN JW: "Highdose" calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32:89-95, 1987
24. DABBAGH S, CHESNEY RW: Treatment of renal osteodystrophy during childhood, in End-Stage Renal Disease in Children, edited by FINE RN, GRUSKIN AB, Philadelphia, W.B. Saunders, 1984, p 251
25. BERGER N, MEHLS O, SCHMITT CP, OH J: Daily calcitriol but not pulse therapy improves growth in experimental uremia. (abstract) J Am Soc Nephrol 7:1787, 1996
26. SANCHEZ CP, SALUSKY IB, KUIZON BD, WILLSEY P, GALES B, JÜPPNER H, GOODMAN WG: Effects of growth hormone and calcitriol on PTH/PTHrP receptor mRNA expression on rat growth plate cartilage. (abstract) J Am Soc Nephrol 7:1796, 1996
27. 3 inhibits cell growth and chondrogenesis of a clonal mouse EC cell line, ATDC5. J Bone Miner Res 11:22-28, 1996
28. KATO Y, SHIMAZU A, IWAMOTO M, NAKASHIMA K, KOIKE T, SUZUKI F, NISHII Y, SATO K: Role of 1,25-dihydroxycholecalciferol in growth-plate cartilage: Inhibition of terminal differentiation of chondrocytes, in vitro and in vivo. Proc Natl Acad Sci USA 87:6522-6526, 1990
29. FARQUHARSON C, WHITEHEAD CC, RENNIE JS, LOVERIDGE N: In vivo effect of 1,25-dihydroxycholecalciferol on the proliferation and differentiation of avian chondrocytes. J Bone Miner Res 8:1081-1088, 1993
30. KLAUS G, MEINHOLD-HEERLEIN R, MILDE P, RITZ E, MEHLS O: Effect of vitamin D on growth cartilage cell proliferation in vitro. Pediatr Nephrol 5:461-466, 1991
31. LANSKE B, KARAPLIS AC, LEE K, LUZ A, VORTKAMP A, PIRRO A, KARPERIEN M, DEFIZE LHK, HO C, MULLIGAN RC, ABOU-SAMRA AB, JÜPPNER H, SEGRE GV, KRONENBERG HM: PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663-666, 1996
32. VORTKAMP A, LEE K, LANSKE B, SEGRE GV, KRONENBERG HM, TABIN CJ: Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613-622, 1996
33. KARAPLIS AC, LUZ A, GLOWACKI J, BRONSON RT, TYBULEWICZ VLJ, KRONENBERG HM, MULLIGAN RC: Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Gene Dev 8:277-289, 1994
34. SCHIPANI E, LANGMAN CB, PARFITT AM, JENSEN GS, KIKUCHI S, KOOH SW, COLE WG, JÜPPNER H: Constituitively activated receptors for parathyroid hormone and parathyroid hormone related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med 335:708-714, 1996
35. WEIR EC, PHILBRICK WM, AMLING M, NEFF LA, BARON R, BROADUS AE: Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc Natl Acad Sci USA 93:10240-10245, 1996
36. UREÑA P, KUBRUSLY M, MANNSTADT M, HRUBY M, TAN MTT, SILVE C, LACOUR B, ABOU-SAMRA A-B, SEGRE GV, DRÜEKE TB: The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 45:605-611, 1994
37. 3 in the osteoblast-like ROS 17/2.8 cells. Am J Physiol (Endocrinol Metab) E654-E660, 1996
38. MALLUCHE HH, FAUGERE MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int 42(Suppl 38):S62-S67, 1992
39. SHERRARD DJ, HERCZ G, PEI Y, MALONEY N, GREENWOOD C, MANUEL A, SAIPHOO C, FENTON SS, SEGRE GV: The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 43:436-442, 1993
40. HERCZ G, PEI Y, GREENWOOD C, MANUEL A, SAIPHOO C, GOODMAN WG, SEGRE GV, FENTON S, SHERRARD DJ: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
41. HERCZ G, SHERRARD DJ, CHAN W, PEI Y: Aplastic osteodystrophy: Follow-up after 5 years. (abstract) J Am Soc Nephrol 5:851, 1994